chufangao/CTO huggingface dataset:
Clinical trial NCT03373383: Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Acronym: ARISE
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 411.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-02-12
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Baseline population: Baseline characteristics refer to the Randomized Set (RS) consisting of all participants randomized into the study.
Plan to share individual participant data: YES
IPD sharing description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT03614923: Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Official title: A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis
Sponsor: AnaptysBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-29
Primary completion date: 2020-09-02
Completion date: 2020-10-26
Plan to share individual participant data: NO
Clinical trial NCT04254978: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
Official title: A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 73.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-08
Primary completion date: 2023-03-23
Completion date: 2023-03-23
Plan to share individual participant data: NO
Clinical trial NCT04761887: Cool Pre-operative TAP Blocks
Official title: Pilot Study on the Thermal Effects of Local Anesthetics
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study withdrawn prior to enrollment (insufficient funds and reduced access to patients related to COVID protocols)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-31
Primary completion date: 2022-12-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT04504032: A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
Official title: A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19
Sponsor: Bill & Melinda Gates Medical Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.
Enrollment: 497.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-02
Primary completion date: 2021-03-10
Completion date: 2021-03-29
Limitations and caveats: Based on Data Monitoring Committee's recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.
Plan to share individual participant data: YES
Clinical trial NCT04617847: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
Official title: A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease
Sponsor: Wave Life Sciences Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-13
Primary completion date: 2021-05-03
Completion date: 2021-05-03
Plan to share individual participant data: NO
Clinical trial NCT04903327: Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
Official title: Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to considerably slow enrollment, unable to reach enrollment targets
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-16
Primary completion date: 2022-08-29
Completion date: 2022-11-23
Clinical trial NCT04088500: A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Official title: A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-03
Primary completion date: 2021-11-15
Completion date: 2021-11-15
Limitations and caveats: The study was terminated early, leading to small numbers of participants analyzed.
Clinical trial NCT03556345: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Official title: A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer
Sponsor: RemeGen Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 127.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-10
Primary completion date: 2020-06-01
Completion date: 2020-08-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05921929: First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
Official title: Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
Sponsor: ReST Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: a new trial should be designed
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-05-02
Primary completion date: 2024-05-02
Completion date: 2024-05-02
Clinical trial NCT04523571: Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
Official title: Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study
Sponsor: BioNTech SE (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 144.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-07-28
Primary completion date: 2020-09-30
Completion date: 2021-08-10
Plan to share individual participant data: NO
Clinical trial NCT02618434: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Official title: Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Sponsor: Supernus Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 297.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-02-16
Primary completion date: 2019-11-15
Completion date: 2020-02-14
Baseline population: Intent-to-Treat (ITT) Population: The ITT population includes subjects who received at least one dose of the study drug and have a baseline and at least one valid post-randomization assessment of the frequency of IA behaviors based on an IA diary entry.
Clinical trial NCT04032171: Study of Evobrutinib in Participants With RMS
Official title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With RMS to Evaluate Efficacy and Safety
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-10
Primary completion date: 2020-05-20
Completion date: 2020-05-20
Baseline population: Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early, therefore no participants enrolled in Avonex® + Evobrutinib matched Placebo arm.
Limitations and caveats: Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early, therefore, it was decided as per Statistical Analysis Plan not to report the efficacy data for this study.
Plan to share individual participant data: YES
IPD sharing description: Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html.
Clinical trial NCT01526135: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
Official title: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Sponsor: UNICANCER (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 493.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-04-16
Primary completion date: 2018-03-31
Completion date: 2021-07-16
Clinical trial NCT02547116: Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
Official title: Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Administrative delay
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT02891798: 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans
Official title: 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans
Sponsor: VA Pittsburgh Healthcare System (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 98.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-31
Primary completion date: 2021-07-12
Completion date: 2021-08-20
Baseline population: Veterans undergoing hip/knee replacement surgery completing the study course
Limitations and caveats: The sample size determined before the study began was N=100 patients to undergo primary THA and N=100 patients to undergo primary TKA, with these patients not undergoing physical therapy until day-one after surgery; these sample sizes were ultimately not achieved. By early 2018, same-day physical therapy (after surgery) became the new hospital guideline for patients undergoing primary THA and TKA, such that by mid-2018, the study was interrupted. Only the described 78 patients completed.
Plan to share individual participant data: NO
Clinical trial NCT05153499: A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides Difficile Infection (CDI)
Acronym: PRISM4
Sponsor: Finch Research and Development LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The termination of FIN-CDI-301 (PRISM4) is based on the voluntary, business-related decision of the sponsor.
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-15
Primary completion date: 2023-02-24
Completion date: 2023-02-24
Baseline population: Intent to Treat (ITT) population used.
Limitations and caveats: Study was terminated early. Most analyses were not performed.
Clinical trial NCT00589316: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Official title: Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to loss of funding
Enrollment: 26.0 (ACTUAL)
Number of arms: 1.0
Start date: 2007-10-05
Primary completion date: 2016-10-01
Completion date: 2021-10-01
Limitations and caveats: Study accrual has been lower (i.e., 26 total) than the planned target accrual of 50 due to the prioritization of other clinical trials using an alternative radiometal (yttrium-90 \[90Y\]) and antibody construct (BC8-DOTA).
Clinical trial NCT02833207: Peripheral Vasodilation in Obese Humans
Official title: Peripheral Vasodilation in Obese Humans
Acronym: ObeseDilate
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to COVID-19, difficulty obtaining study drugs, difficulty recruiting obese subjects, and limited access to on-call physicians.
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2012-04-16
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT03087851: Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Official title: Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Acronym: ZOLARMAB
Sponsor: Aarhus University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-13
Primary completion date: 2020-08-01
Completion date: 2020-08-01
Limitations and caveats: Open-label design, no assessment by VFA or X-ray of VFx at baseline, changes in treatment not in accordance with the protocol. Information about BMD before initiation of DMAB is not available and the BMD loss can therefore not be evaluated in the context of the BMD gain during DMAB. Our p-CTX cutoff was 50% above the normal range for postmenopausal women and elderly men and it cannot be ruled out that the outcome of the study would have been different with a different cutoff.
Plan to share individual participant data: NO
Clinical trial NCT04434131: Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
Official title: Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
Sponsor: University of New Mexico (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-28
Primary completion date: 2020-07-31
Completion date: 2021-03-12
Plan to share individual participant data: NO
Clinical trial NCT04116164: Safety and Targeting of Anti-hk2 Antibody in mCRPC
Official title: A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer.
Sponsor: SpectronRX (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-18
Primary completion date: 2023-07-06
Completion date: 2023-07-06
Plan to share individual participant data: NO
Clinical trial NCT03967093: A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Official title: A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors
Acronym: KOURAGE
Sponsor: Bexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Bexion will not move forward with the Part 2 expansion portion of the trial in order to focus resources on the further development of BXQ-350 as an earlier treatment measure in the pediatric population.
Enrollment: 9.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-04-15
Primary completion date: 2020-01-03
Completion date: 2020-01-17
Plan to share individual participant data: NO
Clinical trial NCT02625090: An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
Official title: An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
Enrollment: 42.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-03
Primary completion date: 2020-11-24
Completion date: 2020-11-24
Baseline population: Baseline Characteristics refer to the Safety Set (SS) consisted of all enrolled study participants who took at least 1 dose of UCB0942 in the EP0073 study.
Clinical trial NCT03888534: Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Official title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory Acute Lymphoblastic Leukemia, With or Without Extramedullary Disease, or Relapsed or Refractory Lymphoblastic Lymphoma
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business decision (no safety or efficacy concerns)
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-31
Primary completion date: 2022-08-30
Completion date: 2022-08-30
Plan to share individual participant data: YES
IPD sharing description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Clinical trial NCT02510261: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Official title: A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 211.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-07-16
Primary completion date: 2022-11-23
Completion date: 2022-11-23
Baseline population: Full analysis set included all participants who were enrolled in this study.
Plan to share individual participant data: NO
Clinical trial NCT02867332: PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Official title: A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma
Sponsor: Peking University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-30
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: UNDECIDED
IPD sharing description: plan to do